In an editorial, one expert said the choice of DOAC in VTE is “no longer a toss-up,” with apixaban the clear winner.

Apixaban conferred lower bleeding risk during a 3-month period compared with rivaroxaban in patients with acute venous thromboembolism, researchers reported.Despite higher medication adherence to ...

Favorable safety shown in secondary prevention for acute venous thromboembolism ...

Apixaban halved the risk for bleeding compared with rivaroxaban in the treatment of acute venous thromboembolism in the ...

Courts may deny motions for judgment notwithstanding the verdict when a jury reaches a reasonable decision based on evidence of a patient's failure to follow a prescribed treatment plan.

The PAUSE-URO study evaluated the safety of a new protocol for patients using direct oral anticoagulants (DOACs) prior to elective urologic surgery.

Venous thromboembolism includes deep vein thrombosis (DVT) and pulmonary embolism, which have incidence rates of between 1 and 2 cases per 1000 people for the first episode.1,2 Strong, provoking risk ...

Significantly lower risk for clinically relevant bleeding seen with apixaban than rivaroxaban during three-month trial period.

The first clinical trial to compare two commonly used drugs head-to-head for venous thrombosis treatment has found a clear ...